MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202547097015 A) filed by Cancer Research Technology Limited; and My-T Bio Limited, London, on Oct. 8, for 'biarylamide derivatives and their use as pkmyt1 inhibitors.'
Inventor(s) include Raoof, Ali; Spyridon-Gavriil, Efthymios; Niculescu-Duvaz, Dan; Brown, Michaelepo; Smithen, Deborah; Fitzpatrick, Christopher; Grytsai, Oleksandr; Aljarah, Mohammed; Lisauskaite, Monika; Burgin, Ryan; Kershaw, Christopher Stephen; Leung, Leo; Hagan, Iain; Marais, Richard; and Springer, Caroline.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain biarylamide compounds of the following formula (also referred to herein as "BAA compounds") which inhibit Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKMYT1 kinase; to treat disorders (e.g., diseases) that are ameliorated by the inhibition of PKMYT1 kinase; to treat a proliferative disorder, cancer, etc."
The patent application was internationally filed on Mar. 08, 2024, under International application No.PCT/EP2024/056305.
Disclaimer: Curated by HT Syndication.
